Sam Brusco, Associate Editor01.05.24
Covalon has appointed Brent Ashton, a longtime 3M Health Care and BD executive, as its new CEO. He will also join the company’s board.
He was most recently at BD, serving as VP and GM for the company’s specimen management business group. Before BD, he spent 13 years at 3M Health Care, in roles ranging from global business director to business unit VP. In his most recent role there, he led commercial and cross-functional efforts for its patient preparation and management business unit.
Ashton said, "I am extremely excited about the opportunity to lead Covalon and its talented and dedicated team to further success. Covalon has exceptional, compassionate medical products that make a real difference to patients and the clinicians who treat them. As CEO, I look forward to meeting the needs of our prestigious customers and supporting our team as we deliver on our strategic priorities and drive both long-term growth and value creation for our shareholders.”
With Ashton’s appointment, interim CEO Amir Baloor has resigned and will take on the role of Covalon’s executive chair.
said, “On behalf of the Board, I am delighted to welcome Mr. Brent Ashton to Covalon as its new CEO,” said Baloor Brent’s extensive MedTech industry expertise specifically as it relates to our products and end-markets as well as his strategic leadership and demonstrated track record of driving both top and bottom-line growth will play a crucial part in fast-tracking Covalon's growth journey. As we remain committed to fortifying our operations and prioritizing both profitability and sustained growth, Brent's valuable contributions will be instrumental in achieving our strategic objectives."
Covalon’s portfolio includes technologies and solutions for advanced wound care, infection prevention, and medical device coatings.
He was most recently at BD, serving as VP and GM for the company’s specimen management business group. Before BD, he spent 13 years at 3M Health Care, in roles ranging from global business director to business unit VP. In his most recent role there, he led commercial and cross-functional efforts for its patient preparation and management business unit.
Ashton said, "I am extremely excited about the opportunity to lead Covalon and its talented and dedicated team to further success. Covalon has exceptional, compassionate medical products that make a real difference to patients and the clinicians who treat them. As CEO, I look forward to meeting the needs of our prestigious customers and supporting our team as we deliver on our strategic priorities and drive both long-term growth and value creation for our shareholders.”
With Ashton’s appointment, interim CEO Amir Baloor has resigned and will take on the role of Covalon’s executive chair.
said, “On behalf of the Board, I am delighted to welcome Mr. Brent Ashton to Covalon as its new CEO,” said Baloor Brent’s extensive MedTech industry expertise specifically as it relates to our products and end-markets as well as his strategic leadership and demonstrated track record of driving both top and bottom-line growth will play a crucial part in fast-tracking Covalon's growth journey. As we remain committed to fortifying our operations and prioritizing both profitability and sustained growth, Brent's valuable contributions will be instrumental in achieving our strategic objectives."
Covalon’s portfolio includes technologies and solutions for advanced wound care, infection prevention, and medical device coatings.